Table IV.

Maintained tumor and peptide-reactivity by PBMC after adoptive immunotherapy^a

		g209 Peptide (μM)					g209-2M	MART-1	HLA-A2+		HLA-A2+
Patient	PBL Sample	1	0.1	0.01	0.001	0.0001	1	1	526mel	624mel	888mel	938mel
3	Pre	427	395	401	355	324	470	315	108	101	130	81
	Infusion	9660	8030	3540	706	204	14330	156	2270	3110	115	93
	1 wk	2270	1800	621	241	119	3500	94	854	676	24	28
	1 mo	2730	1800	758	241	81	4320	52	1467	1324	21	23
4	Pre	16	15	22	3	11	16	27	21	29	15	25
	Infusion	1580	1345	618	153	71	1990	61	558	391	17	13
	1 wk	1258	1139	309	87	29	1790	31	299	291	9	42
	1 mo	2100	1409	1073	301	70	2490	45	1376	576	4	13
	2 mo	717	723	405	141	26	946	43	457	149	33	37
5	Pre	32	27	14	32	22	50	20	21	12	0	1
	Infusion	7680	6920	2670	392	136	12160	78	2630	2330	18	45
	1 wk	3710	3050	931	198	63	6340	58	1340	1700	2	17
	1 mo	3000	1399	647	236	54	6870	42	2020	1404	0	31
	2 mo	2990	2290	1061	303	93	6410	87	2060	1700	45	87
8	Pre	84	42	37	13	24	97	33	47	47	10	10
	Infusion	5460	4680	1910	283	103	9250	71	1173	2270	55	18
	1 wk	1370	1539	787	225	44	2210	59	1194	1063	46	25
	1 mo	1016	733	559	168	106	795	69	688	438	44	26
9	Pre	91	81	37	42	50	198	48	23	25	10	10
	Infusion	5030	3230	897	204	123	10110	112	706	724	30	24
	2 mo	2190	1455	771	163	47	6280	50	1139	576	18	7

^aIFN-γ secretion (pg/ml) from patient pretreatment PBMC, peptide-stimulated cells used for infusion, and postinfusion PBMC stimulated with HLA-A2⁺ (526 and 624) or HLA-A2⁺ (888 and 938) melanoma cell lines, or T2 APC pulsed with gp100:209–217 (g209), gp100:209–217(210M) (g209-2M), or MART-1:26–35(27L) (MART-1) peptide at the indicated concentration. Cryopreserved cells were thawed and rested overnight in CM and recombinant human IL-2 (300 IU/ml) before establishment of cocultures. Underlined, bold face values represent specific cytokine secretion specified as > 2-fold increase compared to controls and > 100 pg/ml concentration.